Disease Atlas / Disease detail

Kaposi sarcoma

An evidence-led guide to HHV-8-associated vascular tumors, disease extent, immune status, and anticancer treatment.

Kaposi sarcoma · Kaposi's sarcoma · KS

MONDO:0005055Public QA completeSource-bound · 4

Disease at a glance

Start with the essentials, then explore the patient and research views.

Public revision · e5bf964788c2

Disease class: Kaposi sarcoma is a vascular tumor associated with human herpesvirus 8.
Core mechanism: HHV-8 infection alone does not cause tumors in everyone; immune status is important in disease development.
Genes or cause: Clinical forms include classic, endemic, transplant-associated, and HIV-associated Kaposi sarcoma.
Typical features: Purple or brown lesions can affect skin or oral tissues, and lymph nodes or internal organs may also be involved.
Variability: Symptoms and risk vary with disease extent, visceral involvement, immune status, and comorbidity.
Diagnosis: Diagnosis is confirmed by biopsy and pathologic evaluation of a suspected lesion.
Management: Staging evaluates skin and oral lesions, edema, lymph nodes, and visceral involvement such as lung or gastrointestinal disease.
Treatment and research: Effective antiretroviral therapy is central to treatment of HIV-associated Kaposi sarcoma.
Reading evidence: Local therapy may be considered for limited lesions, while extensive or symptomatic disease may require systemic chemotherapy.
Key caution: Treatment selection considers clinical form, tempo, organ involvement, potential immune recovery, and treatment toxicity.

A structured guide for understanding the disease and preparing for clinical conversations.

Kaposi sarcoma is a vascular tumor associated with human herpesvirus 8.

Purple or brown lesions can affect skin or oral tissues, and lymph nodes or internal organs may also be involved.

HHV-8 infection alone does not cause tumors in everyone; immune status is important in disease development.

Clinical forms include classic, endemic, transplant-associated, and HIV-associated Kaposi sarcoma.

Symptoms and risk vary with disease extent, visceral involvement, immune status, and comorbidity.

Diagnosis is confirmed by biopsy and pathologic evaluation of a suspected lesion.

Staging evaluates skin and oral lesions, edema, lymph nodes, and visceral involvement such as lung or gastrointestinal disease.

Effective antiretroviral therapy is central to treatment of HIV-associated Kaposi sarcoma.

Follow-up assesses lesion number and size, symptoms, organ involvement, and changes in immune and virologic measures.

Clinical discussion should separately address pathology, HIV and immune status, disease extent, treatment goals, and medication risks.

This material is for disease education and is not a personal diagnosis or treatment instruction.

A trial registry status does not establish efficacy or regulatory approval.